The amendments to the claims are merely correct antecedent basis and to conform the claims to United States Patent practice. These amendments do not add new matter.

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: December 5, 2002

By: Carol P. Einaudi

Carol P. Einaudi
Reg. No. 32,220
Phone: (202) 408-4000
Fax: (202) 408-4400
E-mail: carol.einaudi@finnegan.com

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Appendix to the Preliminary Amendment of December 5, 2002

IN THE SPECIFICATION:

Please amend the paragraph bridging pages 21 and 22 as follows:

Antibodies generated against the IGS1 polypeptides may be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a nonhuman, using routine protocols. For preparation of monoclonal antibodies , any technique, which provides antibodies produced by continuous cell line cultures, may be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., Nature (1975) 256:495-497), the trioma technique, the B-cell hybridoma technique ([Kozbor et al., Immunology Today (1983) 4: 72] Kozbor, D. and Roder, J.C. (1983) The production of monoclonal antibodies from human lymphocytes, Immunology Today, vol. 4, pp. 72-79) and the EBV-hybridoma technique (Cole et al., MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc., 1985).

IN THE CLAIMS:

Please amend the following claims:

1. (AMENDED) An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

a) a nucleotide sequence encoding the IGS1 polypeptide according to SEQ ID NO:2;

b) a nucleotide sequence [encoding the polypeptide encoded by] of the DNA insert contained in the deposit no. CBS 102049 [at the Centraalbureau voor

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Schimmelcultures at Baarn the Netherlands, in particular a] wherein the nucleotide sequence [corresponding to] is SEQ ID NO:1;

c) a nucleotide sequence having at least 80% [(preferably at least 90%)] sequence identity [over its entire length] to the nucleotide sequence of (a) or (b); and

d) a nucleotide sequence [which] that is [complimentary] complementary to the nucleotide sequence of (a) or (b) or (c).

2. (AMENDED) The polynucleotide of claim 1, wherein said polynucleotide comprises the nucleotide sequence [contained in] of SEQ ID NO:1, and wherein the nucleotide sequence encodes an [encoding the] IGS1 polypeptide of SEQ ID NO:2.

3. (AMENDED) The polynucleotide of claim 1 wherein said polynucleotide comprises a nucleotide sequence that is at least 80% identical to that of SEQ ID NO:1 [over its entire length].

6. (AMENDED) [A DNA or RNA molecule comprising an] An expression system comprising a DNA or RNA molecule, wherein said expression system [is capable of producing] produces an IGS1 polypeptide comprising an amino acid sequence, which has at least 80% identity with the polypeptide of SEQ ID NO:2 when said expression system is present in a [compatible] host cell.

11. (AMENDED) A process for producing an IGS1 polypeptide comprising culturing a host cell of claim 7 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture.

12. (AMENDED) A process for producing a cell which produces an IGS1 polypeptide [thereof] comprising transforming or transfecting a cell with the expression

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

system of claim 6, [such that] wherein the cell[, under appropriate culture conditions, is capable of producing] produces an IGS1 polypeptide.

13. (AMENDED) An IGS1 polypeptide comprising an amino acid sequence, which is at least 80% identical to the amino acid sequence of SEQ ID NO:2 [over its entire length].

16. (AMENDED) A method for the treatment of a subject in need of enhanced activity or expression of the IGS1 polypeptide [receptor] of claim 13 comprising at least one of:

(a) administering to the subject a therapeutically effective amount of an agonist to said [receptor] polypeptide; [and/or] and

(b) providing to the subject an isolated polynucleotide comprising a nucleotide sequence that has at least 80% identity to a nucleotide sequence encoding the IGS1 polypeptide of SEQ ID NO:2 [over its entire length;] or a nucleotide sequence complementary to said nucleotide sequence [in a form so as to effect], wherein the polynucleotide directs production of said [receptor] polypeptide activity in vivo.

17. (AMENDED) A method for the treatment of a subject having need to inhibit activity or expression of a IGS1 polypeptide [receptor of] as claimed in claim 13 comprising at least one of:

(a) administering to the subject a therapeutically effective amount of an antagonist to said polypeptide; [receptor; and/or]

(b) providing to the subject an isolated polynucleotide that inhibits the expression of the nucleotide sequence encoding said polypeptide; [receptor; and/or] and

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

(c) administering to the subject a therapeutically effective amount of a polypeptide that competes with said [receptor] polypeptide for its ligand.

18. (AMENDED) A process for diagnosing a disease or a susceptibility to a disease in a subject, wherein the disease is related to expression or activity of the IGS1 polypeptide of claim 13 in a subject comprising at least one of:

(a) determining the presence or absence of a mutation in the nucleotide sequence encoding said IGS1 polypeptide in the genome of said subject; [and/or] and

(b) analyzing for the presence or amount of the IGS1 polypeptide expression in a sample derived from said subject.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com